Insider Purchases: Inside the Buy
Tag: Funanc1al Edge
Directors' Thirst for Shares of Global Water Resources Seems Unquenchable. Should You Binge on Them?
Insiders are gulping up shares of Global Water Resources, betting big on Arizona’s thirst for growth. But while the company’s outlook is steady, its valuation might leave you parched. Sip wisely. 💧📈
W&T Offshore (WTI): CEO Buys Shares, But the Tide May Still Be Out
W&T Offshore (WTI): Deep Value or Deep Trouble?
Houston’s oil-and-gas veteran has been drilling for 40 years — and shareholders are still waiting to strike gold. With the CEO buying more shares while shorts circle overhead, the battle for the Gulf of America’s future is heating up. Production’s up, cash flow’s steady, and the dividend still drips — but with a stock 97% below its all-time high, is this a comeback story or a cautionary tale?
AngioDynamics (ANGO)’s CEO Bought Shares a Year Ago and Stock Doubled Since: Will They Keep Going Higher?
AngioDynamics insiders bought low and doubled up, while Wall Street funds practically own the company. With MedTech sales surging and earnings around the corner, can $ANGO climb higher — or will tariffs and volatility zap the gains?
CEO Bought Shares Higher A Year Ago. Will RH Restore Investor Confidence?
RH stock has crashed, but its CEO is still buying, funds are backing, and Paris is shining. With shorts circling and debt looming, is RH a comeback story—or just a fancy couch with shaky legs?
Insiders Think Marvell Is a Wonder at Current Price; Should You Emulate the CEO, CFO, and Presidents and Buy MRVL?
Insiders, buybacks, and AI growth — oh my! Marvell Technology’s execs just bought millions in stock. With a $5B buyback, should you marvel too?
CEO Bought Shares of Vertex Pharmaceuticals (VRTX) A Bit Higher Back in August: Great Biotech At A Fair Price. Wait For Additional Pull-Back?
Vertex is more than cystic fibrosis drugs. With gene editing, pain relief, and even a potential T1D cure, the CEO’s insider buy raises one question: buy now or wait for additional pullback?
Executive Chairman Adds To His Already Huge Stake in Ryan Specialty Holdings. Should You Follow His Lead?
Executive Chairman Patrick Ryan just added $14M to his already massive stake in Ryan Specialty Holdings. With strong revenue growth and heavy institutional backing, is this insurance play worth your portfolio — or is it still too pricey?
Insiders Pile Into Opendoor (OPEN) as New CEO Kasra Nejatian Bets on an ‘AI-First, Software-First’ Future — Should You Join the Cult Stock Rally?
Insiders are buying, retail traders are chanting, and Opendoor has a new AI-first CEO. From near-delisting to cult stock darling — is OPEN worth the hype?
Elon Musk Invests $1 Billion in TSLA. Buy Shares Or Miss the AI/Robotics/Autonomous/Clean Energy Revolution?
Elon Musk just dropped $1 billion of his own cash into Tesla (TSLA). Institutions remain heavily invested, shorts are scarce, and Tesla is betting big on AI, Robotaxis, and clean energy. Is it time to buy—or time to buckle up?
Keurig Dr Pepper (KDP) Insiders Have Been Buying Shares. What’s Brewing?
Insiders are brewing confidence in Keurig Dr Pepper (KDP) with fresh stock buys, while institutions are holding heavy. With a mega coffee deal, spinoff plans, and steady results, is this stock about to perk up or get watered down?